Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Income from Continuing Operations (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Income from Continuing Operations readings, the most recent being 13720000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 61.18% to 13720000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 78259000.0, a 122.78% decrease, with the full-year FY2025 number at 78259000.0, down 122.78% from a year prior.
  • Income from Continuing Operations hit 13720000.0 in Q4 2025 for Avalo Therapeutics, up from 30625000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 98463000.0 in Q2 2024 to a low of 121290000.0 in Q1 2024.
  • Median Income from Continuing Operations over the past 5 years was 13434500.0 (2025), compared with a mean of 13546550.0.
  • The widest YoY moves for Income from Continuing Operations: up 1301.79% in 2024, down 1118.38% in 2024.
  • Avalo Therapeutics' Income from Continuing Operations stood at 19131000.0 in 2021, then skyrocketed by 48.71% to 9812000.0 in 2022, then rose by 16.75% to 8168000.0 in 2023, then crashed by 332.65% to 35339000.0 in 2024, then skyrocketed by 61.18% to 13720000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 13720000.0 (Q4 2025), 30625000.0 (Q3 2025), and 20765000.0 (Q2 2025) per Business Quant data.